Shopping Cart
Remove All
Your shopping cart is currently empty
FW1256
Copy Product Info
😃Good
Catalog No. T15361Cas No. 117089-08-4
FW1256 is a phenyl analog. It also a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and causes cell apoptosis. FW1256 shows potent anti-inflammatory effects. It also has the potential for cancer and cardiovascular disease treatment.
FW1256
Copy Product Info😃Good
Catalog No. T15361Cas No. 117089-08-4
FW1256 is a phenyl analog. It also a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and causes cell apoptosis. FW1256 shows potent anti-inflammatory effects. It also has the potential for cancer and cardiovascular disease treatment.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,430 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,860 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 6-8 weeks |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | FW1256 is a phenyl analog. It also a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and causes cell apoptosis. FW1256 shows potent anti-inflammatory effects. It also has the potential for cancer and cardiovascular disease treatment. |
| In vitro | FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment obviously decreases IL-1β, COX-2, iNOS PROTE, and iNOS mRNA and protein in LPS-stimulated RAW264.7 macrophages. FW1256 reduces NF-κB activation as evidenced by reduced cytosolic phospho-IκBα levels and reduces nuclear p65 levels in LPS-stimulated RAW264.7 macrophages treated with FW1256. FW1256 concentration-dependently reduces TNF-α (IC50: 61.2 μM), IL-6 (IC50: 11.7 μM), PGE2 (IC50: 25.5 μM) and NO (IC50: 34.6 μM) generation in LPS-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs) (IC50s: 414.9 μM, 300.2 μM, 4 μM and 9.5 μM for TNF-α, IL-6, PGE2 and NO, respectively) [1]. |
| In vivo | Treatment with FW1256 (100 mg/kg; i.p.; male C57BL/6 mice), decreases IL-1β, TNFα, nitrate/nitrite, and PGE2 levels in LPS-treated mice [1]. |
| Molecular Weight | 247.25 |
| Formula | C12H10NOPS |
| Cas No. | 117089-08-4 |
| Smiles | S=P1(NC=2C(O1)=CC=CC2)C3=CC=CC=C3 |
| Relative Density. | 1.37 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (1011.12 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy FW1256 | purchase FW1256 | FW1256 cost | order FW1256 | FW1256 chemical structure | FW1256 in vivo | FW1256 in vitro | FW1256 formula | FW1256 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.